El c\u00e1ncer de pulm\u00f3n es uno de los m\u00e1s prevalentes, con m\u00e1s de 20.000 nuevos casos diagnosticados cada a\u00f1o en Espa\u00f1a. En el 30% interviene el oncog\u00e9n KRAS, que hace que el tumor sea m\u00e1s agresivo. Asimismo, es un tipo de c\u00e1ncer de pulm\u00f3n que no cuenta con terapias dirigidas m\u00e1s all\u00e1 del est\u00e1ndar con cisplatino.
\nUn estudio encabezado por los investigadores Mariano Barbacid y David Santamaia, del Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), y en el que tambi\u00e9n ha participado un equipo del ICO-IDIBELL formado por Alberto Villanueva y Ernest Nadal, ha identificado una posible nueva estrategia para hacer frente a estos tumores.
\nEl estudio, que se ha hecho en modelos de ratones, se publica en la revista Nature Medicine y muestra c\u00f3mo la combinaci\u00f3n dirigida de los f\u00e1rmacos desatinib -inhibidores de la prote\u00edna DDR1- y demcizumab -un anticuerpo inhibidor de la v\u00eda de Notch- reduce de forma espec\u00edfica y eficaz los tumores y mejora sustancialmente el pron\u00f3stico y la supervivencia. Completados los estudios precl\u00ednicos, el siguiente paso es hacer los ensayos cl\u00ednicos que validen la combinaci\u00f3n de estos f\u00e1rmacos para el tratamiento de los adenocarcinomas de pulm\u00f3n.
\nLos autores del trabajo han utilizado modelos precl\u00ednicos de rat\u00f3n modificados gen\u00e9ticamente. Tambi\u00e9n se han estudiado en orthoxenografts\u00ae de c\u00e1ncer de pulm\u00f3n, que son modelos ortot\u00f3picos generados por la implementaci\u00f3n de tumores humanos en el pulm\u00f3n del rat\u00f3n, generados por el equipo de Alberto Villanueva al ICO-IDIBELL \/ Xenopat S.L. Estos modelos, los m\u00e1s avanzados que existen en c\u00e1ncer de pulm\u00f3n, permiten estudiar la eficacia de los f\u00e1rmacos directamente sobre muestras humanas.<\/b><\/b><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"
El c\u00e1ncer de pulm\u00f3n es uno de los m\u00e1s prevalentes, con m\u00e1s de 20.000 nuevos casos diagnosticados cada a\u00f1o en Espa\u00f1a. En el 30% interviene el oncog\u00e9n KRAS, que hace que el tumor sea m\u00e1s agresivo. Asimismo, es un tipo de c\u00e1ncer de pulm\u00f3n que no cuenta con terapias dirigidas m\u00e1s all\u00e1 del est\u00e1ndar con […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,281,206],"tags":[],"class_list":["post-10635","post","type-post","status-publish","format-standard","hentry","category-area-cancer","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell","category-quimioresistencia-tumoral-y-estromal"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 12:57:42","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=10635"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10635\/revisions"}],"predecessor-version":[{"id":18026,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10635\/revisions\/18026"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=10635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=10635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=10635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}